Literature DB >> 18573106

Review article: the hepatic manifestations of hereditary haemorrhagic telangiectasia.

C Sabbà1, M Pompili.   

Abstract

BACKGROUND: Liver involvement in hereditary haemorrhagic telangiectasia is mainly characterized by vascular malformations, such as telangiectasies and arteriovenous shunts, which are found in up to 80% of patients. AIM: To analyse the current knowledge and controversies regarding the epidemiological, pathological, clinical, diagnostic and therapeutic aspects of liver involvement in hereditary haemorrhagic telangiectasia. Methods Systematic survey analysis of the indexed studies dealing with the above mentioned topics.
RESULTS: No more than 8% of patients with hepatic vascular abnormalities will have a symptomatic liver disease, mainly consisting in high-output heart failure, portal hypertension or biliary disease.
CONCLUSIONS: Colour Doppler ultrasonography is a non-invasive, highly accurate and relatively low-cost procedure for the screening of liver involvement in patients with hereditary haemorrhagic telangiectasia; computed tomography, magnetic resonance imaging and angiography can be reserved for the characterization of focal lesions and the study of severely ill patients in whom invasive therapeutic procedures are advisable. Patients with asymptomatic liver involvement should not receive any treatment, while the therapeutic options for symptomatic patients include treatment of the specific complication, invasive procedures for shunt reduction and liver transplantation. The newly developed antiangiogenetic therapies appear to be very promising, but still require further evaluation in clinical trials.

Entities:  

Mesh:

Year:  2008        PMID: 18573106     DOI: 10.1111/j.1365-2036.2008.03775.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  Successful liver transplantation for Rendu-Weber-Osler disease, a single centre experience.

Authors:  Murat Cag; Maxime Audet; Anne-Catherine Saouli; Murad Odeh; Bernard Ellero; Tullio Piardi; Marie-Lorraine Woehl-Jaeglé; Jacques Cinqualbre; Philippe Wolf
Journal:  Hepatol Int       Date:  2011-02-17       Impact factor: 6.047

2.  Two for the price of one: a dual treatment benefit of long-acting octreotide in occult bleeding and diuretic intractable ascites.

Authors:  Bee Leng Lee; Jeff Turner; Joanna Hurley; John Green; Neil Hawkes; Ruth Alcolado
Journal:  Frontline Gastroenterol       Date:  2011-07-26

3.  Putting a new spin: MRI monitoring of hepatic artery and portal vein flow for response to bevacizumab in hereditary hemorrhagic telangiectasia.

Authors:  Numan Kutaiba; Paul J Gow; Janine French; Ruth P Lim
Journal:  Clin Case Rep       Date:  2014-11-17

Review 4.  Optimal management of hereditary hemorrhagic telangiectasia.

Authors:  Neetika Garg; Monica Khunger; Arjun Gupta; Nilay Kumar
Journal:  J Blood Med       Date:  2014-10-15

5.  Pancytopenia in a Patient with Rendu-Osler-Weber Syndrome and Uncommon Vascular Abnormalities.

Authors:  Nicolò Binello; Antonio Gasbarrini; Eleonora Gaetani
Journal:  Case Rep Hematol       Date:  2016-10-10

Review 6.  [Liver involvement in Rendu-Osler disease: a case report and review of literature].

Authors:  Hanen Loukil; Mouna Snoussi; Hela Fourati; Faten Frikha; Raida Ben Salah; Moez Jallouli; Sameh Marzouk; Zeineb Mnif; Zouhir Bahloul
Journal:  Pan Afr Med J       Date:  2016-08-25

7.  High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment.

Authors:  Lilian B Olsen; Anette D Kjeldsen; Mikael K Poulsen; Jens Kjeldsen; Annette D Fialla
Journal:  Orphanet J Rare Dis       Date:  2020-11-26       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.